SCHEMBL2733243

SCHEMBL2733243

O=C(OCc1ccccc1)N1CCN(Cc2ccncn2)CC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 6/20 0.57
▸ CYP2D6 P10635 4/20 0.57
▸ CYP2C9 P11712 4/20 0.57
▸ CYP3A4 P08684 3/20 0.57
▸ KDM4E B2RXH2 3/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ FNTA P49354 2/20 0.50
▸ FNTB P49356 2/20 0.50
▸ PGGT1B P53609 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ CYP2C19 P33261 1/20 0.47
▸ OPRD1 P41143 1/20 0.47
▸ OPRK1 P41145 1/20 0.47
▸ GRM5 P41594 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17485677 0.87 KDM4E (0.74) GRIN2BKDM4EALDH1A1MEN1KMT2A
SCHEMBL13150170 0.84 KDM4E (0.60) GRIN2BCYP2D6CYP2C9CYP3A4KDM4E
SCHEMBL5714373 0.80 ALDH1A1 (0.49) KDM4EALDH1A1NPSR1
SCHEMBL8263854 0.80 ALDH1A1 (0.55) GRIN2BCYP2D6CYP2C9CYP3A4KDM4E
SCHEMBL3970912 0.78 MEN1 (0.76) GRIN2BCYP2D6CYP2C9ALDH1A1MEN1
SCHEMBL7393652 0.78 MEN1 (0.76) GRIN2BCYP2D6CYP2C9ALDH1A1MEN1
SCHEMBL4814264 0.78 MEN1 (0.76) GRIN2BCYP2D6CYP2C9ALDH1A1MEN1
SCHEMBL379160 0.78 MEN1 (0.76) GRIN2BCYP2D6CYP2C9ALDH1A1MEN1
SCHEMBL23301332 0.77 FAAH (0.61) GRIN2BKDM4EALDH1A1MEN1KMT2A
SCHEMBL13150429 0.77 FAAH (0.63) GRIN2BKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2632457-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2017-03-22 — — EP disclosed
US-8933102-B2 Pyrrolidine derived β3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2015-01-13 — — US disclosed
EP-2470021-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-10-22 — — EP disclosed
EP-2632457-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS Merck Sharp & Dohme Corp. (US) 2013-09-04 — — EP disclosed
US-20130225599-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS Life Technologies Corporation (US) 2013-08-29 — — US disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 — — US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 — — US disclosed
WO-2012058130-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2012-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 GRIN2B 1257/4885CYP2D6 1147/4885CYP2C9 1267/4885
US-20130225599-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 GRIN2B 888/4885CYP2D6 824/4885CYP2C9 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback